CSIMarket
 
Prelude Therapeutics Inc  (PRLD)
Other Ticker:  
 
 
Price: $4.1800 $-0.73 -14.868%
Day's High: $4.98 Week Perf: -19.92 %
Day's Low: $ 4.10 30 Day Perf: -6.28 %
Volume (M): 69 52 Wk High: $ 7.25
Volume (M$): $ 288 52 Wk Avg: $4.06
Open: $4.80 52 Wk Low: $1.66



 Market Capitalization (Millions $) 283
 Shares Outstanding (Millions) 68
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) -36
 Capital Exp. (TTM) (Millions $) 3

Prelude Therapeutics Inc
Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops innovative small molecule therapies for the treatment of cancer and other serious diseases. The company was founded in 2016 and is headquartered in Wilmington, North Carolina, with additional offices in New York City and Shanghai.

Prelude Therapeutics Inc. focuses on developing therapies that target signaling pathways that are critical for cancer growth and progression. The company's lead product candidate, PRT543, is a potent and selective inhibitor of PRMT5, an enzyme that is essential for the growth and survival of several types of cancer cells. PRT543 has shown promising preclinical activity in a variety of solid tumors and hematological malignancies, including diffuse large B-cell lymphoma, multiple myeloma, and acute myeloid leukemia.

In addition to PRT543, Prelude Therapeutics Inc. has a pipeline of other small molecule inhibitors that target key oncogenic signaling pathways, including Wnt, Notch, and Hedgehog. The company's approach is based on the belief that using a combination of targeted agents that attack different pathways may lead to more effective and durable responses in patients with cancer.

Prelude Therapeutics Inc. has a team of experienced pharmaceutical executives and scientists who have a track record of developing successful cancer therapies. The company has also established collaborations with leading academic and research institutions to accelerate the discovery and development of new therapeutics.

Overall, Prelude Therapeutics Inc. is a promising biopharmaceutical company that is focused on developing innovative therapies for the treatment of cancer and other serious diseases. With a robust pipeline of small molecule inhibitors and a team of experienced scientists and executives, the company has the potential to make a significant impact in the field of oncology.


   Company Address: 200 Powder Mill Road Wilmington 19803 DE
   Company Phone Number: 467-1280   Stock Exchange / Ticker: NASDAQ PRLD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Highly Selective Oral SMARCA2 Degrader, PRT7732, Demonstrates Potent Anti-Tumor Activity in Preclinical Models and Promising Synergistic Effects with Chemotherapy

Published Tue, Apr 9 2024 8:35 PM UTC

The American Association for Cancer Research (AACR) held its annual meeting in 2024, where an exciting breakthrough in cancer research was unveiled by Prelude Therapeutics Inc. The event provided a platform to highlight the continued strength of Prelude's discovery engine, with special focus on their novel orally available SMARCA2 degrader, PRT7732. This article aims to delv...

Clinical Study

Prelude Therapeutics' Promising Pipeline: Innovations Creating Potential Breakthroughs in Cancer Research

Published Thu, Feb 15 2024 9:05 PM UTC

In the competitive world of pharmaceutical research, companies constantly strive to innovate and develop cutting-edge therapies that can revolutionize patient care. In this article, we delve into the latest update from Prelude Therapeutics, a renowned biotechnology company specializing in oncology. We analyze their recently released full year 2023 financial results and exami...

Financing Agreement

Prelude Therapeutics Secures $25 Million in Private Placement to Propel Precision Oncology Advancements

Published Mon, Dec 11 2023 2:34 PM UTC



Prelude Therapeutics Incorporated, a leading clinical-stage precision oncology company, recently unveiled its plans for a private placement earmarked to raise an estimated $25 million in gross proceeds. This funding will play a crucial role in supporting the continued development of Prelude's highly promising SMARCA2 portfolio, in addition to bolstering its working...

Prelude Therapeutics Inc

Prelude Therapeutics Inc Faces Investor Concerns as Operating Deficit Swells to $33.4 Million in Q3 2023


Date: October 14, 2023
Prelude Therapeutics Inc (Nasdaq: PRLD), a clinical-stage precision oncology company, recently announced its financial results for the earnings cycle of fiscal July to September 30, 2023. The stockholders did not anticipate any modifications to the company's top-line during this period. However, Prelude Therapeutics reported an operating deficit of $-33.385 million, raising concerns among investors.
Although the company has not disclosed its revenue figures yet, it is essential to compare the latest results with the previous year's third quarter (Q3) to gain a better perspective. In Q3 2022, the company experienced an operating deficit of $-30.406 million. The current deficit marks a slight increase in losses.
Prelude Therapeutics Inc is actively pursuing various financial plans to ensure stability and introduce a new product line. These plans are expected to play a crucial role in improving the company's financial health and potential revenue streams.

Prelude Therapeutics Inc

Prelude Therapeutics Inc. Soars as Ascendant Star in Major Pharmaceutical Preparations Market Despite Q2 2023 Earnings Season Deficit

In the midst of the ongoing earnings season for the period between April and June 30, 2023, numerous companies have announced their respective financial results. Among them are several constituents of the Major Pharmaceutical Preparations industry. One such company, Prelude Therapeutics Inc, recently revealed an operating deficit of $-32.398 million for the second quarter of the earnings season.
In the financial period ending on June 30, 2023, Prelude Therapeutics Inc reported a net shortfall of $-30.431 million. This represents a significant decline compared to the balanced books of the same financial reporting period a year ago. These disappointing financial results have been a cause for concern among investors and analysts.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com